Aridis Pharmaceuticals, Inc.: Nasdaq/NYSE listing notice — Aridis receives Nasdaq delisting notice for late Q1 filing; auditor Baker Tilly resigns

Aridis Pharmaceuticals, Inc.

Nasdaq notified Aridis of additional delisting basis for failure to file Q1 2023 Form 10-Q; Hearings Panel to consider.
Baker Tilly US, LLP resigned as independent auditor effective after filing of Q1 10-Q; company interviewing replacements.
No accounting disagreements with Baker Tilly; material weakness in internal controls was previously disclosed in 2022 10-K.
Aridis has presented its views to Nasdaq Panel regarding continued listing on the Nasdaq Capital Market.

item 3.01 item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Aridis Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding late filing.

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing

Exact text from the filing

May 23, 2023, Aridis Pharmaceuticals, Inc. (the “Company”) received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that Nasdaq had not received the Company’s Form 10-Q for the three months ended March 31, 2023 and this serves as an additional basis for delisting the Company’s securities from The Nasdaq Capital Market. The Notice serves as formal notification that the Nasdaq Hearings Panel (the “Panel”) will consider this matter in their decision regarding the Company’s continued listing on The Nasdaq Capital Market. In that regard, the Company has pre

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001493152-23-019112

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.